#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
John Hey Email
CSO . Alzheon
How to contact John Hey
Join and see John's contact info for free!Current Roles
Employees:
30Revenue:
$3.2MAbout
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.comAlzheon Address
111 Speen Streetnull, null
United States